News | Proton Therapy | October 29, 2015

Ackerman Cancer Center to Install Second Mevion S250 Proton Therapy System

New system will include Hyperscan, Mevion’s high-speed pencil beam scanning technology

Ackerman Cancer Center, second Mevion S250 proton therapy system, Hyperscan, pencil beam scanning technology

Image courtesy of Business Wire

October 29, 2015 — Mevion Medical Systems announced that Ackerman Cancer Center (ACC) in Jacksonville, Florida, will install a second Mevion S250 Series proton therapy system. ACC began treating cancer patients with its first S250 system in April, and is already treating enough patients to warrant the installation of a second system. ACC achieved the fastest per-room ramp-up in the history of proton therapy, reaching an annualized rate of 350 patients per year, more than 25 percent better than the average U.S. proton therapy center.

“The Mevion S250 proton therapy system has been an extremely valuable addition to our cancer center and an important treatment option for our patients, particularly those with tumors in sensitive areas such as the brain or spinal cord,” said Scot Ackerman, M.D., radiation oncologist and medical director of Ackerman Cancer Center. “We are thrilled to begin installing a second Mevion system and to be among the first centers to receive Hyperscan pencil beam scanning technology. Tumor motion and substandard penumbra have limited the use of pencil beam scanning delivery, but with Hyperscan, these limitations are simply eliminated.”

The second ACC system is a Mevion S250i with Hyperscan pencil beam scanning technology, which delivers high-quality intensity modulated proton therapy (IMPT) treatments with precision and robustness. The technology operates at unmatched speeds, volumetrically scanning tumors in less than six seconds, eliminating many of the challenges caused by patient motion that traditional pencil beam scanning solutions encounter. Its tumor targeting capability is further enhanced by its extremely low lateral penumbra.

ACC is the world’s first private, physician-owned cancer center to offer proton therapy, an advanced form of radiation therapy that targets cancer cells more precisely than traditional photon radiation treatment and results in less damage to surrounding healthy tissue and organs. The center has treated patients with a variety of cancers, including brain, breast, esophogeal and lung.

Construction of ACC’s second proton therapy bunker will take place in 2016. The superconducting synchrocyclotron accelerator, a core component of the proton therapy system, will be delivered to the center in late 2016. It is expected to begin treating patients in 2017.

For more information: www.mevion.com

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve